Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729373 | 0.94 | CYP3A4 (0.55) | CCR2CYP3A4 | |
| SCHEMBL4797150 | 0.82 | TACR1 (0.59) | CCR2CYP3A4TACR1 | |
| SCHEMBL4463185 | 0.82 | CCR2 (0.62) | CCR2 | |
| SCHEMBL14081575 | 0.82 | CCR2 (0.62) | CCR2 | |
| SCHEMBL5730547 | 0.80 | CCR2 (0.49) | CCR2CYP3A4TACR1 | |
| Trifluoroacetic Acid SCHEMBL3038763 | 0.78 | TACR1 (0.58) | CCR2CYP3A4TACR1 | |
| SCHEMBL13934259 | 0.77 | CCR2 (0.52) | CCR2TACR1 | |
| SCHEMBL3029890 | 0.77 | CCR2 (0.51) | CCR2CYP3A4 | |
| SCHEMBL13934251 | 0.76 | CCR2 (0.56) | CCR2CYP3A4 | |
| SCHEMBL3038764 | 0.76 | CCR2 (0.48) | CCR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390803-B2 | Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390803-B2 | Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1318811-B1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2006-08-30 | — | — | EP | disclosed |
| US-6545023-B2 | For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR1, CCRL2, CCR5 | CCR2 6/4885CYP3A4 1161/4885TACR1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.